Literature DB >> 18477453

Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding.

Mariana I Capurro1, Ping Xu, Wen Shi, Fuchuan Li, Angela Jia, Jorge Filmus.   

Abstract

Loss-of-function mutations in glypican-3 (GPC3), one of the six mammalian glypicans, causes the Simpson-Golabi-Behmel overgrowth syndrome (SGBS), and GPC3 null mice display developmental overgrowth. Because the Hedgehog signaling pathway positively regulates body size, we hypothesized that GPC3 acts as an inhibitor of Hedgehog activity during development. Here, we show that GPC3 null embryos display increased Hedgehog signaling and that GPC3 inhibits Hedgehog activity in cultured mouse embryonic fibroblasts. In addition, we report that GPC3 interacts with high affinity with Hedgehog but not with its receptor, Patched, and that GPC3 competes with Patched for Hedgehog binding. Furthermore, GPC3 induces Hedgehog endocytosis and degradation. Surprisingly, the heparan sulfate chains of GPC3 are not required for its interaction with Hedgehog. We conclude that GPC3 acts as a negative regulator of Hedgehog signaling during mammalian development and that the overgrowth observed in SGBS patients is, at least in part, the consequence of hyperactivation of the Hedgehog signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477453     DOI: 10.1016/j.devcel.2008.03.006

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  142 in total

1.  Dally-like core protein and its mammalian homologues mediate stimulatory and inhibitory effects on Hedgehog signal response.

Authors:  Elizabeth H Williams; William N Pappano; Adam M Saunders; Min-Sung Kim; Daniel J Leahy; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  The cell-surface proteins Dally-like and Ihog differentially regulate Hedgehog signaling strength and range during development.

Authors:  Dong Yan; Yihui Wu; Yongfei Yang; Tatyana Y Belenkaya; Xiaofang Tang; Xinhua Lin
Journal:  Development       Date:  2010-06       Impact factor: 6.868

3.  Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site.

Authors:  Henry R Maun; Xiaohui Wen; Andreas Lingel; Frederic J de Sauvage; Robert A Lazarus; Suzie J Scales; Sarah G Hymowitz
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

4.  X-linked congenital ptosis and associated intellectual disability, short stature, microcephaly, cleft palate, digital and genital abnormalities define novel Xq25q26 duplication syndrome.

Authors:  R S Møller; L R Jensen; S M Maas; J Filmus; M Capurro; C Hansen; C L M Marcelis; K Ravn; J Andrieux; M Mathieu; M Kirchhoff; O K Rødningen; N de Leeuw; H G Yntema; G Froyen; J Vandewalle; K Ballon; E Klopocki; S Joss; J Tolmie; A C Knegt; A M Lund; H Hjalgrim; A W Kuss; N Tommerup; R Ullmann; A P M de Brouwer; P Strømme; S Kjaergaard; Z Tümer; T Kleefstra
Journal:  Hum Genet       Date:  2013-12-11       Impact factor: 4.132

Review 5.  An introduction to proteoglycans and their localization.

Authors:  John R Couchman; Csilla A Pataki
Journal:  J Histochem Cytochem       Date:  2012-09-26       Impact factor: 2.479

6.  A Membranome-Centered Approach Defines Novel Biomarkers for Cellular Subtypes in the Intervertebral Disc.

Authors:  Guus G H van den Akker; Lars M T Eijssen; Stephen M Richardson; Lodewijk W van Rhijn; Judith A Hoyland; Tim J M Welting; Jan Willem Voncken
Journal:  Cartilage       Date:  2018-04-09       Impact factor: 4.634

Review 7.  Shaping morphogen gradients by proteoglycans.

Authors:  Dong Yan; Xinhua Lin
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09       Impact factor: 10.005

8.  Craniofacial skeletal defects of adult zebrafish Glypican 4 (knypek) mutants.

Authors:  Elizabeth E LeClair; Stephanie R Mui; Angela Huang; Jolanta M Topczewska; Jacek Topczewski
Journal:  Dev Dyn       Date:  2009-10       Impact factor: 3.780

9.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

Review 10.  Glypicans as Cancer Therapeutic Targets.

Authors:  Nan Li; Wei Gao; Yi-Fan Zhang; Mitchell Ho
Journal:  Trends Cancer       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.